549548-33-6

Upstream product

• 598-19-6 2-bromoallyl alcohol 
• 146631-00-7 [4-(benzyloxy)phenyl]boronic acid 
• 68641-16-7 (4-benzyloxy-phenyl)-acetic acid methyl ester 
• 111751-72-5 methyl 2-(4'-benzyloxyphenyl)propenoate 

Downstream Products

• 549548-38-1 (6S,7R,8aS)-6-(4-Benzyloxy-phenyl)-6,7-dihydroxy-7-methyl-hexahydro-indolizin-3-one 
• 549548-35-8 (S)-1-[2-(4-Benzyloxy-phenyl)-allyl]-5-(2-methyl-allyl)-pyrrolidin-2-one 
• 549548-36-9 (S)-1-[2-(4-Benzyloxy-phenyl)-2-oxo-ethyl]-5-(2-oxo-propyl)-pyrrolidin-2-one 
• 549548-37-0 6-(4-benzyloxy-phenyl)-7-methyl-1,5,8,8a-tetrahydro-2H-indolizin-3-one 
• 549548-39-2 (S)-6-(4-Benzyloxy-phenyl)-7-methyl-1,2,3,5,8,8a-hexahydro-indolizine 
• 23506-90-3 4-[(8aS)-7-methyl-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol 
• 549548-34-7 1-Benzyloxy-4-(1-bromomethyl-vinyl)-benzene 

Relevant academic research and scientific papers

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease

To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were identified. Selected compounds were also tested for neuroprotection in in vitro studies with PC-12 cells treated with 6-OHDA and rotenone, respectively. It was observed that some of the compounds tested yielded a marked increase in survival in PC-12 cells treated with the neurotoxins. This indicates that these propargylamines are able to confer protection against the effects of the toxins and may also be considered as novel disease-modifying anti-Parkinsonian agents, which are much needed for the therapy of Parkinson's disease.

Enantiospecific synthesis of an indolizidine alkaloid, (+)-ipalbidine

Enantiospecific total synthesis of an indolizidine alkaloid, ipalbidine, was achieved starting from (-)-pyroglutamic acid by employing an intramolecular McMurry coupling reaction with a low-valent titanium, as a key step.